Treatment with JAK inhibitors in myelofibrosis patients nullifies the prognostic impact of unfavorable cytogenetics

MICRO ABSTRACT: In the era before the advent of JAK inhibitors, cytogenetic information was used to predict survival in myelofibrosis patients. However, the prognostic value of cytogenetics in the setting of JAK inhibitor therapy remains unknown. Our analyses suggest that initiation of JAK inhibitor...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Lymphoma Myeloma Leuk
Päätekijät: Ma, Vincent T., Boonstra, Philip S., Menghrajani, Kamal, Perkins, Cecelia, Gowin, Krisstina L., Mesa, Ruben A., Gotlib, Jason R., Talpaz, Moshe
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5927833/
https://ncbi.nlm.nih.gov/pubmed/29574002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2018.02.019
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia